Serum Amyloid Biomarkers, Tau Protein and YKL-40 Utility in Detection, Differential Diagnosing, and Monitoring of Dementia
Introduction: The diagnosis and treatment of dementia is one of the greatest challenges in contemporary health care. The widespread use of dementia biomarkers would improve the quality of life of patients and reduce the economic costs of the disease. The aim of the study was to evaluate the usefulne...
Main Authors: | Karolina Wilczyńska, Mateusz Maciejczyk, Anna Zalewska, Napoleon Waszkiewicz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.725511/full |
Similar Items
-
Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
by: Karolina Wilczyńska, et al.
Published: (2020-10-01) -
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
by: Franc Llorens, et al.
Published: (2017-11-01) -
Plasma YKL-40 in the spectrum of neurodegenerative dementia
by: Anna Villar-Piqué, et al.
Published: (2019-07-01) -
Study of serum YKL-40 in children with bronchial
by: Iman A. Mohammed, et al.
Published: (2016-03-01) -
Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron
by: Jiajun Han, et al.
Published: (2021-10-01)